Dr. Jennifer Litton is a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is also vice president of clinical research. The 2021 American Society of Clinical Oncology annual meeting was held virtually June 4-8, and there were a number of studies on breast cancer presented. Dr. Litton joined us to talk about some of the most notable research. Listen to the episode to hear her explain: results from the OlympiA trial, showing that Lynparza (chemical name: oliparib) offered benefits for early-stage breast cancer in people with a BRCA1 or BRCA2 mutation results from the NEOTALA trial showing that Talzenna (chemical name: talazoparib) offered benefits for early-stage breast cancer in people with a BRCA1 or BRCA2 mutation when given before surgery updated results showing continued better overall survival when advanced-stage, hormone-receptor-positive, HER2-negative breast cancer is treated with the CDK4/6 inhibitors Ibrance (chemical name: palbociclib) or Kisqali (chemical name: ribociclib)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related